Immunological Markers ofChlamydia trachomatisInfection in Epithelial Ovarian Cancer
Open Access
- 30 August 2023
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 43 (9) , 4037-4043
Abstract
Background/Aim: Pelvic inflammatory disease (PID) is a risk factor for epithelial ovarian cancer (EOC). Chlamydia trachomatis infection, a major cause of PID, may persist in some women. Serum IgG antibodies to chlamydial TroA and HtrA are more common in ascending or repeat chlamydial infection than in uncomplicated infection. The aim of this study was to explore the role of C. trachomatis infection in EOC by analyzing chlamydial TroA, HtrA and major outer membrane protein (MOMP) IgG serum antibody responses. Patients and Methods: The study is based on the review of Oulu University Hospital medical records of 162 women diagnosed with EOC between March 2008 and May 2018. Serum IgG antibody responses to recombinant C. trachomatis TroA, HtrA and MOMP were analyzed using enzyme-linked immunoassay. Complete response to the first line therapy and the three-year survival were the study endpoints. Results: Altogether, 16.7%, 11.1% and 12.3% women were C. trachomatis TroA, HtrA and MOMP IgG positive, respectively. Women with these antibodies were more likely to have a complete response to the first-line treatment, compared to women without these antibodies (63.0% vs. 34.1% for TroA IgG, 50.0% vs. 37.5% for HtrA IgG and 50% vs. 37.3% for MOMP IgG, respectively). The presence of these antibodies predicted better three-year survival. Conclusion: Women with EOC and positive markers of persistent C. trachomatis infection have better response to the first-line treatment and seem to have better three-year survival.Keywords
This publication has 24 references indexed in Scilit:
- Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern SwedenTranslational Oncology, 2020
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancerCancer Epidemiology, 2018
- Serum antibody response to Chlamydia trachomatis TroA and HtrA in women with tubal factor infertilityEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysisCancer Causes & Control, 2017
- Antibody to Chlamydia trachomatis proteins, TroA and HtrA, as a biomarker for Chlamydia trachomatis infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Chlamydia trachomatis as the Cause of Infectious Infertility: Acute, Repetitive or Persistent Long-Term Infection?2016
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- Pelvic Inflammatory DiseaseNew England Journal of Medicine, 2015
- Chlamydia Infection Promotes Host DNA Damage and Proliferation but Impairs the DNA Damage ResponseCell Host & Microbe, 2013